Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin

Diagnostic Microbiology and Infectious Disease
Ronald N JonesRodrigo E Mendes

Abstract

Dalbavancin (DAL) represents a recently approved addition for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Newly released antimicrobial agents are rarely found on commercial susceptibility testing devices, and surrogate testing may be an option for clinical microbiology laboratories. A total of 33,688 Staphylococcus aureus, 2800 viridans group streptococci (VGS), and 5722 β-hemolytic streptococci (BHS) were included in this cross-susceptibility (DAL versus vancomycin [VAN]) analysis as well as 4576 coagulase-negative staphylococci and 6515 enterococci (nonindicated species groups). Isolates were collected as part of the SENTRY Antimicrobial Surveillance Program for the United States (USA) and Europe (2011-2013). Susceptibility testing followed CLSI (M07-A9 and M100-S24) methods. USA Food and Drug Administration (DAL) and CLSI (VAN) breakpoint criteria were used for correlations between DAL and VAN susceptibility results. A categorical agreement (CA; susceptible) rate of 99.9% was observed between DAL and VAN when testing S. aureus. Only 48 (0.14%) very major (false-susceptible) errors were noted against VAN-susceptible isolates that displayed a DAL-nonsusceptible (MIC, 0.25 or 0.5 μg/mL) phenot...Continue Reading

References

Oct 30, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elyse SeltzerUNKNOWN Dalbavancin Skin and Soft-Tissue Infection Study Group
Feb 20, 2004·Diagnostic Microbiology and Infectious Disease·Jennifer M StreitRonald N Jones
Mar 8, 2005·The Journal of Antimicrobial Chemotherapy·Mary Beth DorrTimothy J Henkel
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis E JaureguiWilliam O'Riordan
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Gengrong LinPeter C Appelbaum
Apr 29, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J TurnidgeG Kronvall
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·David Andes, William A Craig
Jan 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marianne BilleterChanga Kurukularatne
Jan 7, 2009·Antimicrobial Agents and Chemotherapy·Douglas J BiedenbachRonald N Jones
Jan 30, 2013·Diagnostic Microbiology and Infectious Disease·Ronald N JonesRobert K Flamm
Feb 26, 2013·Diagnostic Microbiology and Infectious Disease·Ronald N JonesHelio S Sader
Jun 5, 2014·The New England Journal of Medicine·Helen W BoucherMichael W Dunne
Jun 5, 2014·The New England Journal of Medicine·Henry F Chambers

❮ Previous
Next ❯

Citations

Dec 15, 2015·Clinical Therapeutics·Kenneth P Klinker, Samuel J Borgert
Sep 6, 2015·Infectious Diseases and Therapy·Jordan R SmithMichael J Rybak
May 29, 2016·The Medical Clinics of North America·Andrew W HahnDavid H Spach
Apr 18, 2015·Annals of Clinical Microbiology and Antimicrobials·Michael W DunneSailaja Puttagunta
Mar 31, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R M Humphries, J A Hindler
Aug 27, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S Esposito, S Bianchini
Mar 11, 2016·Journal of Clinical Microbiology·Matthew P CrottyDavid J Ritchie
Jul 30, 2020·International Journal of Antimicrobial Agents·Emanuele Durante-MangoniNicola Coppola
Apr 2, 2021·Therapeutics and Clinical Risk Management·Oriana SimonettiAnnamaria Offidani
May 23, 2020·Medicina clínica·Alicia Rico-Nieto, Iker Falces-Romero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.